Brief: Richter signs exclusive license agreement with Hikma Pharmaceuticals

Richter Gedeon Vegyeszeti Gyar Nyrt

09/12/2021 07:04

Dec 9 (Reuters) - Hungary's Richter  says in statement:
    * RICHTER SAYS IT HAS SIGNED EXCLUSIVE COMMERCIALISATION AND
LICENSE AGREEMENT FOR ITS DENOSUMAB, A PROPOSED BIOSIMILAR IN
THE US WITH HIKMA PHARMACEUTICALS PLC
    * RICHTER WILL BE ELIGIBLE FOR AN UPFRONT PAYMENT UPON
SIGNATURE
AS WELL AS CERTAIN MILESTONE PAYMENTS UNDER THE AGREEMENT WITH
HIKMA
    * PAYMENTS ARE LINKED TO REACHING DEFINED DEVELOPMENT
STAGES,
TOTALLING A DOUBLE-DIGIT MILLION USD FIGURE 
    * RICHTER IS RESPONSIBLE FOR THE DEVELOPMENT OF THE PRODUCTS
AND
WILL SUPPLY FINISHED COMMERCIAL PRODUCTS FOR THE US MARKET 
    * DENOSUMAB IS MARKETED UNDER TWO BRANDS, IT IS A BIOSIMILAR
TO
THE REFERENCE PRODUCTS PROLIA AND XGEVA  

Source text for Eikon: [ID:https://bse.hu/newkibdata/128646079/RCH211209ER01E.pdf
]
Further company coverage:  GDRB.BU 

 (Reporting by Krisztina  Than)
 ((Krisztina.Than@thomsonreuters.com;))